As part of his presentation, Dr. Paulini will provide a corporate overview and update on the Company’s lead product, Macrilen™ (macimorelin), the only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Dr. Paulini’s slide presentation will be made available on the Company’s website on Monday, February 17th.
Additionally, the Company issued to the investors unregistered warrants to purchase up to an aggregate of 2,608,696 common shares in a concurrent private placement. The warrants have an exercise price of $1.20 per common share, are exercisable immediately and will expire five and one-half years following the date of issuance. The gross proceeds to the Company from the offering totaled approximately $4.5 million, before deducting placement agent fees and offering expenses.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia ...
The Centre for Monitoring the Indian Economy (CMIE) estimates India’s current unemployment to be 27%, with 122 million Indians rendered jobless during this pandemic.
– Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ – – Robust ongoing business development.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 8.) Allergan plc (NYSE: AGN ): AbbVie Inc ...
This study, AEZS-130-P01 (“Study P01”), was the first of two studies as agreed with the European Medicines Agency (“EMA”) in the Company’s Pediatric Investigation Plan (“PIP”) for macimorelin. The goal of Study P01 was to establish a dose that could both be safely administered to pediatric patients and cause a clear rise in growth hormone concentration in subjects ultimately diagnosed as not having GHD.
CHARLESTON, S.C., April 15, 2020 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company.
– Modifications recommended for some key elements of planned safety and efficacy Study P02 – – Modifications to the outline of Study P02 requested to ensure a harmonized global.
A live audio webcast of the presentation will be available on the Events and Presentations page of the Investors section of the Company’s website (www.zentaris.com). The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Shareholders will not be able to attend the AGM in-person at a physical location. To be admitted to the virtual AGM, shareholders need to visit www.virtualshareholdermeeting.com/AEZS2020 and enter the control number included on the proxy form or voting instruction form, as applicable. Aeterna Zentaris strongly encourages its shareholders to read its management proxy circular dated April 2, 2020 and other AGM materials carefully.
The Company also provided an update on its clinical program to develop macimorelin for the diagnosis of child-onset growth hormone deficiency (“CGHD”), an area of significant unmet need, and its plans to expand macimorelin for the diagnosis of adult growth hormone deficiency (“AGHD”) in Europe. With these positive Study P01 results, we have the necessary data to lay the foundation for our test validation, Study P02, which we expect to commence later this year.
The offering is expected to result in gross proceeds to Aeterna Zentaris of approximately $4.5 million. Aeterna Zentaris will also issue to the purchasers unregistered warrants to purchase up to an aggregate of 2,608,696 common shares. The warrants will be exercisable for a period of five and one-half years, exercisable immediately following the issuance date and have an exercise price of $1.20 per common share.
Timothy C. Wentworth, Express Scripts Holding Company and Cigna Services President, joins Yahoo Finance’s Alexis Christoforous and Brian Sozzi to discuss how health insurance companies are faring amid the coronavirus outbreak.
– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic – – Study.
Aeterna Zentaris Inc. (AEZS) (AEZS) today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") indicating that, because the closing bid price of the Company’s common stock for 30 consecutive business days was below $1.00 per share, the Company no longer meets the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
The individuals noted below were elected as Directors of the Company. The Company would like to welcome Peter Edwards to the Board of Directors. The Company would also like to extend its sincere thanks and best wishes to Gérard Limoges, Dr. Brent Norton, and Robin Smith Hoke who have been valued members of Aeterna’s Board of Directors.
NEW YORK, May 4, 2020 /PRNewswire/ -- A new medical development is sweeping the country. Some may see it as controversial - but the studies don't lie. It's effective. So effective, in fact, that the FDA has just fast-tracked approval for research, meaning tha…
CHARLESTON, S.C., Jan. 27, 2020 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in.
The settlement payment will be funded entirely by the Company’s insurers. The previously disclosed class-action lawsuit alleged that the Company and certain of its current and former officers and directors violated the Securities Exchange Act of 1934 in connection with certain public statements made between August 30, 2011 and November 6, 2014, regarding the safety and efficacy of Macrilen™ (macimorelin) and the prospects for the approval of the Company's New Drug Application for the product by the FDA.
Gilead Sciences’ antiviral drug remdesivir showed “quite good news,” according to White House health advisor Dr. Anthony Fauci. Assistant Professor in Department of Health Policy and Management at the Harvard Global Health Institute Dr. Tom Tsai joins Yahoo Finance’s Seana Smith to discuss the latest developments.